Abstract PO2-15-06: ctDNA-based DNADX in hormone receptor-positive and HER2-negative (HR+/HER2-) advanced breast cancer following endocrine therapy and CDK4/6 inhibition: a correlative analysis from the randomized phase 2 PARSIFAL trial
Year: 2024
Type: conference-abstract
Source: Cancer Research
Authors: Fara Brasó-Maristany, Javier Cortés, José Manuel Pérez-García, Rosario Vega-León, Laia Paré, Guillermo Villacampa, Judit Matito, Francisco Pardo, Marina Gomez-Rey, Mario Mancino, Elena Martínez-García, Carmen Mora Gallardo, Leonardo Mina, Florence Dalenc, Meritxell Bellet- Ezquerra, Manuel Ruíz - Borrego, Miguel Gil-Gil, Peter Schmid, Charles M. Perou, Joel S. Parker, Patricia Villagrasa, Ana Vivancos, Aleix Prat, Antonio Llombart-Cussac
Institutions: Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, MedSIR (Spain), Universidad Europea de Madrid, Vall d'Hebron Institute of Oncology, Institut universitaire du cancer de Toulouse Oncopole, Vall d'Hebron Hospital Universitari, Hospital Universitario Virgen del Rocío, Institut Català d'Oncologia, GEICAM – Spanish Breast Cancer Group, Queen Mary University of London, Barts Cancer Institute, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Hospital Clínic de Barcelona, Hospital Arnau de Vilanova
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4396587912